Amgen v. Sanofi: The US Supreme Court Reviews Patent Enablement

被引：0

作者：

Curfman, Gregory ^{[1
,2
]}

Boumil, Marcia M. ^{[3
]}

机构：

[1] JAMA, Chicago, NY 60611 USA

[2] Yale Univ, New Haven, CT 06520 USA

[3] Tufts Univ, Boston, MA USA

来源：

JOURNAL OF LAW MEDICINE & ETHICS | 2023年 / 51卷 / 03期

关键词：

Monoclonal Antibodies; Patent Enablement; Genus Patent Claims; PCSK9; Inhibitors; LDL Receptors;

D O I：

10.1017/jme.2023.102

中图分类号：

B82 [伦理学（道德学）];

学科分类号：

摘要：

On June 18, 2023, the U.S. Supreme Court in the matter of Amgen, Inc. et al. v. Sanofi, et al.(1) unanimously upheld the 2021 decision of the U.S. Court of Appeals for the Federal Circuit,(2) striking down as overbroad Amgen's patent claim to an entire functional genus of monoclonal antibodies. Amgen's patent claims were not limited to antibody structure or antibody amino acid sequences. This is significant because Amgen's patent claims did have amino acid sequences, but they were directed to the epitope.

引用

页码：689 / 693

页数：5

共 12 条

[1] [Anonymous], Amgen, Inc. et. al. v. Sanofi, et al., No. 21-757, P7
[2] [Anonymous], Amgen, Inc. et. al. v. Sanofi, et al., No.21-757, P2
[3] [Anonymous], 2023, Amgen, Inc. et. al v. Sanofi, et al
[4] [Anonymous], 1966, Brenner v. Mason
[5] [Anonymous], 2023, Amgen, Inc. et. al. v. Sanofi, et al., No. 21-757, Heritage Rep. Corp.,, P56
[6] [Anonymous], 1871, Mowry v. Whitney
[7] Patenting Laws of Nature Effect on Cardiovascular Innovation
Boumil, Marcia M.
Curfman, Gregory
[J]. JAMA CARDIOLOGY, 2018, 3 (11) : 1031 - 1032
[8] Fala Loretta, 2016, Am Health Drug Benefits, V9, P136
[9] Holman D., Case Studies and Trends at the PTAB Involving 35 U.S.C. 112
[10] sgp.fas, 2022, CRS Report, Patent-Eligble Sub- ject Matter Reform: Background and Issues for Congress, No.R-45918

← 1 2 →